9473 related articles for article (PubMed ID: 19951637)
21. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
23. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
24. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott R; Ali F; Burdette-Radoux S
Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
[TBL] [Abstract][Full Text] [Related]
25. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark.
Bentzen J; Kjellberg J; Thorgaard C; Engholm G; Phillip A; Storm HH
Eur J Cancer Prev; 2013 Nov; 22(6):569-76. PubMed ID: 23542376
[TBL] [Abstract][Full Text] [Related]
26. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
27. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
28. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
Wilson LS; Reyes CM; Lu C; Lu M; Yen C
Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
[TBL] [Abstract][Full Text] [Related]
29. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of therapies for melanoma.
Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
32. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
Crott R
Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
35. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.
Stokes ME; Black L; Benedict A; Roehrborn CG; Albertsen P
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521
[TBL] [Abstract][Full Text] [Related]
36. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
37. Health Outcomes and Direct Healthcare Costs in Patients with Melanoma: Associations with Level of Education.
Buja A; Rivera M; Zorzi M; Sperotto M; Baracco S; Italiano I; Vecchiato A; Del Fiore P; Avossa F; Corti MC; Guzzinati S; Saia M; Baldo V; Rugge M; Rossi CR
Acta Derm Venereol; 2020 Jan; 100(1):adv00003. PubMed ID: 31580466
[No Abstract] [Full Text] [Related]
38. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Livingstone E; Krajewski C; Eigentler TK; Windemuth-Kieselbach C; Benson S; Elsenbruch S; Hauschild A; Rompel R; Meiss F; Mauerer A; Kähler KC; Dippel E; Möllenhoff K; Kilian K; Mohr P; Utikal J; Schadendorf D
Eur J Cancer; 2015 Mar; 51(5):653-67. PubMed ID: 25638778
[TBL] [Abstract][Full Text] [Related]
39. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
[TBL] [Abstract][Full Text] [Related]
40. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]